Loading…

Completion and Adverse Drug Events of Latent Tuberculosis Infection Treatment in Patients Receiving Dialysis: Predictors and Impacts of Different Regimens in a Prospective Cohort Study

Although patients with end-stage renal disease receiving maintenance hemodialysis are at high risk for tuberculosis, the optimal treatment regimen for latent tuberculosis infection (LTBI) in this group has scarcely been studied for predictors of completion rate and adverse drug events (ADE). We pros...

Full description

Saved in:
Bibliographic Details
Published in:Antimicrobial agents and chemotherapy 2021-02, Vol.65 (3)
Main Authors: Lin, Shu-Yung, Feng, Jia-Yih, Lee, Chih-Yuan, Lin, Yi-Chih, Chou, Yu-Hsiang, Lin, Kuan-Yin, Wei, Yu-Feng, Lin, Shu-Wen, Chang, Chin-Hao, Wang, Ping-Huai, Shu, Chin-Chung, Wang, Jann-Yuan, Yu, Chong-Jen
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-a418t-2bb547c73e82ebb213ba85571d6e97e5eec6445f9e88857538bcd6a923f7deed3
cites cdi_FETCH-LOGICAL-a418t-2bb547c73e82ebb213ba85571d6e97e5eec6445f9e88857538bcd6a923f7deed3
container_end_page
container_issue 3
container_start_page
container_title Antimicrobial agents and chemotherapy
container_volume 65
creator Lin, Shu-Yung
Feng, Jia-Yih
Lee, Chih-Yuan
Lin, Yi-Chih
Chou, Yu-Hsiang
Lin, Kuan-Yin
Wei, Yu-Feng
Lin, Shu-Wen
Chang, Chin-Hao
Wang, Ping-Huai
Shu, Chin-Chung
Wang, Jann-Yuan
Yu, Chong-Jen
description Although patients with end-stage renal disease receiving maintenance hemodialysis are at high risk for tuberculosis, the optimal treatment regimen for latent tuberculosis infection (LTBI) in this group has scarcely been studied for predictors of completion rate and adverse drug events (ADE). We prospectively enrolled dialysis patients for LTBI intervention from three medical centers in Taiwan. LTBI treatments were 3 months of weekly rifapentine plus isoniazid (3HP) and 9 months of daily isoniazid (9H). Completion rate, ADE, and reasons for treatment termination were recorded. Factors associated with treatment termination and ADE were analyzed using multivariate logistic regression. In all, 91 treatment courses (41 9H and 50 3HP) were surveyed. The completion rates were 61% for 9H and 82% for 3HP (  = 0.046). Use of 9H and development of ADE with a grade of ≥2 (≥grade 2 ADE) were associated with treatment termination. Hypersensitivity occurred in 29.2% of subjects in the 3HP group and 10.8% in the 9H group (  = 0.035) and independently correlated with 3HP regimen, diabetes mellitus (DM), and peritoneal dialysis (PD). Similarly, the independent predictors of ≥grade 2 ADE were use of 3HP regimen, presence of DM, and use of PD, whereas ≥grade 3 ADE were associated with eosinophil counts of >700/mm after 2 weeks of LTBI treatment even after adjustment for age and gender. In conclusion, for patients on dialysis, 3HP showed a higher rate of completion but also a higher rate of ≥grade 2 ADE than 9H. In addition, DM and PD were risk factors for ≥grade 2 ADE. Eosinophilia after 2-week treatment might be an alert for severe ADE.
doi_str_mv 10.1128/AAC.02184-20
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8092540</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2473420423</sourcerecordid><originalsourceid>FETCH-LOGICAL-a418t-2bb547c73e82ebb213ba85571d6e97e5eec6445f9e88857538bcd6a923f7deed3</originalsourceid><addsrcrecordid>eNp1ks1u1DAUhS0EokNhxxp5CRIpjn8ShwXSKFNgpJGoyrC2HOdm6iqJg51Emjfj8XBmSgULVrblc75zr68Rep2SqzSl8sN6XV4RmkqeUPIErVJSyCQTRfYUrQjJsoRLwi_QixDuSTyLgjxHF4yxLKUFXaFfpeuGFkbreqz7Gq_rGXwAvPHTAV_P0I8Buwbv9Bi3eD9V4M3UumAD3vYNmJNx70GP3SKwPb7Roz3ZbsGAnW1_wBur22O0fMQ3HmprRufDKW3bDdqcEza2acAvjFs42AgLC0xHhwvDkjMDLt2d8yP-Pk718SV61ug2wKuH9RL9-Hy9L78mu29ftuV6l2ieyjGhVSV4bnIGkkJV0ZRVWgqRp3UGRQ4CwGSci6YAKaXIBZOVqTNdUNbkNUDNLtGnM3eYqg5qEyv0ulWDt532R-W0Vf_e9PZOHdysJCmo4CQC3j4AvPs5QRhVZ4OBttU9uCkoynPGKeGURen7s9TEpoOH5jEmJWoZtorDVqdhK7qQ353lOnRU3bvJ9_El_qd983cbj-A_P4H9BlP5tns</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2473420423</pqid></control><display><type>article</type><title>Completion and Adverse Drug Events of Latent Tuberculosis Infection Treatment in Patients Receiving Dialysis: Predictors and Impacts of Different Regimens in a Prospective Cohort Study</title><source>American Society for Microbiology</source><source>PubMed Central</source><creator>Lin, Shu-Yung ; Feng, Jia-Yih ; Lee, Chih-Yuan ; Lin, Yi-Chih ; Chou, Yu-Hsiang ; Lin, Kuan-Yin ; Wei, Yu-Feng ; Lin, Shu-Wen ; Chang, Chin-Hao ; Wang, Ping-Huai ; Shu, Chin-Chung ; Wang, Jann-Yuan ; Yu, Chong-Jen</creator><creatorcontrib>Lin, Shu-Yung ; Feng, Jia-Yih ; Lee, Chih-Yuan ; Lin, Yi-Chih ; Chou, Yu-Hsiang ; Lin, Kuan-Yin ; Wei, Yu-Feng ; Lin, Shu-Wen ; Chang, Chin-Hao ; Wang, Ping-Huai ; Shu, Chin-Chung ; Wang, Jann-Yuan ; Yu, Chong-Jen</creatorcontrib><description>Although patients with end-stage renal disease receiving maintenance hemodialysis are at high risk for tuberculosis, the optimal treatment regimen for latent tuberculosis infection (LTBI) in this group has scarcely been studied for predictors of completion rate and adverse drug events (ADE). We prospectively enrolled dialysis patients for LTBI intervention from three medical centers in Taiwan. LTBI treatments were 3 months of weekly rifapentine plus isoniazid (3HP) and 9 months of daily isoniazid (9H). Completion rate, ADE, and reasons for treatment termination were recorded. Factors associated with treatment termination and ADE were analyzed using multivariate logistic regression. In all, 91 treatment courses (41 9H and 50 3HP) were surveyed. The completion rates were 61% for 9H and 82% for 3HP (  = 0.046). Use of 9H and development of ADE with a grade of ≥2 (≥grade 2 ADE) were associated with treatment termination. Hypersensitivity occurred in 29.2% of subjects in the 3HP group and 10.8% in the 9H group (  = 0.035) and independently correlated with 3HP regimen, diabetes mellitus (DM), and peritoneal dialysis (PD). Similarly, the independent predictors of ≥grade 2 ADE were use of 3HP regimen, presence of DM, and use of PD, whereas ≥grade 3 ADE were associated with eosinophil counts of &gt;700/mm after 2 weeks of LTBI treatment even after adjustment for age and gender. In conclusion, for patients on dialysis, 3HP showed a higher rate of completion but also a higher rate of ≥grade 2 ADE than 9H. In addition, DM and PD were risk factors for ≥grade 2 ADE. Eosinophilia after 2-week treatment might be an alert for severe ADE.</description><identifier>ISSN: 0066-4804</identifier><identifier>EISSN: 1098-6596</identifier><identifier>DOI: 10.1128/AAC.02184-20</identifier><identifier>PMID: 33361292</identifier><language>eng</language><publisher>United States: American Society for Microbiology</publisher><subject>Clinical Therapeutics</subject><ispartof>Antimicrobial agents and chemotherapy, 2021-02, Vol.65 (3)</ispartof><rights>Copyright © 2021 American Society for Microbiology.</rights><rights>Copyright © 2021 American Society for Microbiology. 2021 American Society for Microbiology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a418t-2bb547c73e82ebb213ba85571d6e97e5eec6445f9e88857538bcd6a923f7deed3</citedby><cites>FETCH-LOGICAL-a418t-2bb547c73e82ebb213ba85571d6e97e5eec6445f9e88857538bcd6a923f7deed3</cites><orcidid>0000-0003-0311-5148 ; 0000-0003-3406-366X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.asm.org/doi/pdf/10.1128/AAC.02184-20$$EPDF$$P50$$Gasm2$$H</linktopdf><linktohtml>$$Uhttps://journals.asm.org/doi/full/10.1128/AAC.02184-20$$EHTML$$P50$$Gasm2$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,3174,27903,27904,52730,52731,52732,53770,53772</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33361292$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lin, Shu-Yung</creatorcontrib><creatorcontrib>Feng, Jia-Yih</creatorcontrib><creatorcontrib>Lee, Chih-Yuan</creatorcontrib><creatorcontrib>Lin, Yi-Chih</creatorcontrib><creatorcontrib>Chou, Yu-Hsiang</creatorcontrib><creatorcontrib>Lin, Kuan-Yin</creatorcontrib><creatorcontrib>Wei, Yu-Feng</creatorcontrib><creatorcontrib>Lin, Shu-Wen</creatorcontrib><creatorcontrib>Chang, Chin-Hao</creatorcontrib><creatorcontrib>Wang, Ping-Huai</creatorcontrib><creatorcontrib>Shu, Chin-Chung</creatorcontrib><creatorcontrib>Wang, Jann-Yuan</creatorcontrib><creatorcontrib>Yu, Chong-Jen</creatorcontrib><title>Completion and Adverse Drug Events of Latent Tuberculosis Infection Treatment in Patients Receiving Dialysis: Predictors and Impacts of Different Regimens in a Prospective Cohort Study</title><title>Antimicrobial agents and chemotherapy</title><addtitle>Antimicrob Agents Chemother</addtitle><addtitle>Antimicrob Agents Chemother</addtitle><description>Although patients with end-stage renal disease receiving maintenance hemodialysis are at high risk for tuberculosis, the optimal treatment regimen for latent tuberculosis infection (LTBI) in this group has scarcely been studied for predictors of completion rate and adverse drug events (ADE). We prospectively enrolled dialysis patients for LTBI intervention from three medical centers in Taiwan. LTBI treatments were 3 months of weekly rifapentine plus isoniazid (3HP) and 9 months of daily isoniazid (9H). Completion rate, ADE, and reasons for treatment termination were recorded. Factors associated with treatment termination and ADE were analyzed using multivariate logistic regression. In all, 91 treatment courses (41 9H and 50 3HP) were surveyed. The completion rates were 61% for 9H and 82% for 3HP (  = 0.046). Use of 9H and development of ADE with a grade of ≥2 (≥grade 2 ADE) were associated with treatment termination. Hypersensitivity occurred in 29.2% of subjects in the 3HP group and 10.8% in the 9H group (  = 0.035) and independently correlated with 3HP regimen, diabetes mellitus (DM), and peritoneal dialysis (PD). Similarly, the independent predictors of ≥grade 2 ADE were use of 3HP regimen, presence of DM, and use of PD, whereas ≥grade 3 ADE were associated with eosinophil counts of &gt;700/mm after 2 weeks of LTBI treatment even after adjustment for age and gender. In conclusion, for patients on dialysis, 3HP showed a higher rate of completion but also a higher rate of ≥grade 2 ADE than 9H. In addition, DM and PD were risk factors for ≥grade 2 ADE. Eosinophilia after 2-week treatment might be an alert for severe ADE.</description><subject>Clinical Therapeutics</subject><issn>0066-4804</issn><issn>1098-6596</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp1ks1u1DAUhS0EokNhxxp5CRIpjn8ShwXSKFNgpJGoyrC2HOdm6iqJg51Emjfj8XBmSgULVrblc75zr68Rep2SqzSl8sN6XV4RmkqeUPIErVJSyCQTRfYUrQjJsoRLwi_QixDuSTyLgjxHF4yxLKUFXaFfpeuGFkbreqz7Gq_rGXwAvPHTAV_P0I8Buwbv9Bi3eD9V4M3UumAD3vYNmJNx70GP3SKwPb7Roz3ZbsGAnW1_wBur22O0fMQ3HmprRufDKW3bDdqcEza2acAvjFs42AgLC0xHhwvDkjMDLt2d8yP-Pk718SV61ug2wKuH9RL9-Hy9L78mu29ftuV6l2ieyjGhVSV4bnIGkkJV0ZRVWgqRp3UGRQ4CwGSci6YAKaXIBZOVqTNdUNbkNUDNLtGnM3eYqg5qEyv0ulWDt532R-W0Vf_e9PZOHdysJCmo4CQC3j4AvPs5QRhVZ4OBttU9uCkoynPGKeGURen7s9TEpoOH5jEmJWoZtorDVqdhK7qQ353lOnRU3bvJ9_El_qd983cbj-A_P4H9BlP5tns</recordid><startdate>20210217</startdate><enddate>20210217</enddate><creator>Lin, Shu-Yung</creator><creator>Feng, Jia-Yih</creator><creator>Lee, Chih-Yuan</creator><creator>Lin, Yi-Chih</creator><creator>Chou, Yu-Hsiang</creator><creator>Lin, Kuan-Yin</creator><creator>Wei, Yu-Feng</creator><creator>Lin, Shu-Wen</creator><creator>Chang, Chin-Hao</creator><creator>Wang, Ping-Huai</creator><creator>Shu, Chin-Chung</creator><creator>Wang, Jann-Yuan</creator><creator>Yu, Chong-Jen</creator><general>American Society for Microbiology</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0311-5148</orcidid><orcidid>https://orcid.org/0000-0003-3406-366X</orcidid></search><sort><creationdate>20210217</creationdate><title>Completion and Adverse Drug Events of Latent Tuberculosis Infection Treatment in Patients Receiving Dialysis: Predictors and Impacts of Different Regimens in a Prospective Cohort Study</title><author>Lin, Shu-Yung ; Feng, Jia-Yih ; Lee, Chih-Yuan ; Lin, Yi-Chih ; Chou, Yu-Hsiang ; Lin, Kuan-Yin ; Wei, Yu-Feng ; Lin, Shu-Wen ; Chang, Chin-Hao ; Wang, Ping-Huai ; Shu, Chin-Chung ; Wang, Jann-Yuan ; Yu, Chong-Jen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a418t-2bb547c73e82ebb213ba85571d6e97e5eec6445f9e88857538bcd6a923f7deed3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Clinical Therapeutics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lin, Shu-Yung</creatorcontrib><creatorcontrib>Feng, Jia-Yih</creatorcontrib><creatorcontrib>Lee, Chih-Yuan</creatorcontrib><creatorcontrib>Lin, Yi-Chih</creatorcontrib><creatorcontrib>Chou, Yu-Hsiang</creatorcontrib><creatorcontrib>Lin, Kuan-Yin</creatorcontrib><creatorcontrib>Wei, Yu-Feng</creatorcontrib><creatorcontrib>Lin, Shu-Wen</creatorcontrib><creatorcontrib>Chang, Chin-Hao</creatorcontrib><creatorcontrib>Wang, Ping-Huai</creatorcontrib><creatorcontrib>Shu, Chin-Chung</creatorcontrib><creatorcontrib>Wang, Jann-Yuan</creatorcontrib><creatorcontrib>Yu, Chong-Jen</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Antimicrobial agents and chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lin, Shu-Yung</au><au>Feng, Jia-Yih</au><au>Lee, Chih-Yuan</au><au>Lin, Yi-Chih</au><au>Chou, Yu-Hsiang</au><au>Lin, Kuan-Yin</au><au>Wei, Yu-Feng</au><au>Lin, Shu-Wen</au><au>Chang, Chin-Hao</au><au>Wang, Ping-Huai</au><au>Shu, Chin-Chung</au><au>Wang, Jann-Yuan</au><au>Yu, Chong-Jen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Completion and Adverse Drug Events of Latent Tuberculosis Infection Treatment in Patients Receiving Dialysis: Predictors and Impacts of Different Regimens in a Prospective Cohort Study</atitle><jtitle>Antimicrobial agents and chemotherapy</jtitle><stitle>Antimicrob Agents Chemother</stitle><addtitle>Antimicrob Agents Chemother</addtitle><date>2021-02-17</date><risdate>2021</risdate><volume>65</volume><issue>3</issue><issn>0066-4804</issn><eissn>1098-6596</eissn><abstract>Although patients with end-stage renal disease receiving maintenance hemodialysis are at high risk for tuberculosis, the optimal treatment regimen for latent tuberculosis infection (LTBI) in this group has scarcely been studied for predictors of completion rate and adverse drug events (ADE). We prospectively enrolled dialysis patients for LTBI intervention from three medical centers in Taiwan. LTBI treatments were 3 months of weekly rifapentine plus isoniazid (3HP) and 9 months of daily isoniazid (9H). Completion rate, ADE, and reasons for treatment termination were recorded. Factors associated with treatment termination and ADE were analyzed using multivariate logistic regression. In all, 91 treatment courses (41 9H and 50 3HP) were surveyed. The completion rates were 61% for 9H and 82% for 3HP (  = 0.046). Use of 9H and development of ADE with a grade of ≥2 (≥grade 2 ADE) were associated with treatment termination. Hypersensitivity occurred in 29.2% of subjects in the 3HP group and 10.8% in the 9H group (  = 0.035) and independently correlated with 3HP regimen, diabetes mellitus (DM), and peritoneal dialysis (PD). Similarly, the independent predictors of ≥grade 2 ADE were use of 3HP regimen, presence of DM, and use of PD, whereas ≥grade 3 ADE were associated with eosinophil counts of &gt;700/mm after 2 weeks of LTBI treatment even after adjustment for age and gender. In conclusion, for patients on dialysis, 3HP showed a higher rate of completion but also a higher rate of ≥grade 2 ADE than 9H. In addition, DM and PD were risk factors for ≥grade 2 ADE. Eosinophilia after 2-week treatment might be an alert for severe ADE.</abstract><cop>United States</cop><pub>American Society for Microbiology</pub><pmid>33361292</pmid><doi>10.1128/AAC.02184-20</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-0311-5148</orcidid><orcidid>https://orcid.org/0000-0003-3406-366X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0066-4804
ispartof Antimicrobial agents and chemotherapy, 2021-02, Vol.65 (3)
issn 0066-4804
1098-6596
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8092540
source American Society for Microbiology; PubMed Central
subjects Clinical Therapeutics
title Completion and Adverse Drug Events of Latent Tuberculosis Infection Treatment in Patients Receiving Dialysis: Predictors and Impacts of Different Regimens in a Prospective Cohort Study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T12%3A18%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Completion%20and%20Adverse%20Drug%20Events%20of%20Latent%20Tuberculosis%20Infection%20Treatment%20in%20Patients%20Receiving%20Dialysis:%20Predictors%20and%20Impacts%20of%20Different%20Regimens%20in%20a%20Prospective%20Cohort%20Study&rft.jtitle=Antimicrobial%20agents%20and%20chemotherapy&rft.au=Lin,%20Shu-Yung&rft.date=2021-02-17&rft.volume=65&rft.issue=3&rft.issn=0066-4804&rft.eissn=1098-6596&rft_id=info:doi/10.1128/AAC.02184-20&rft_dat=%3Cproquest_pubme%3E2473420423%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a418t-2bb547c73e82ebb213ba85571d6e97e5eec6445f9e88857538bcd6a923f7deed3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2473420423&rft_id=info:pmid/33361292&rfr_iscdi=true